205 related articles for article (PubMed ID: 19534821)
1. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
[TBL] [Abstract][Full Text] [Related]
2. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
3. Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer.
Wu WC; Jin DY; Lou WH; Wang DS; Qin XY
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1861-8. PubMed ID: 20229033
[TBL] [Abstract][Full Text] [Related]
4. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
5. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
6. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
7. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
8. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
[TBL] [Abstract][Full Text] [Related]
9. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
[TBL] [Abstract][Full Text] [Related]
11. A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo.
Lü F; Qin ZY; Yang WB; Qi YX; Li YM
World J Gastroenterol; 2004 Jul; 10(14):2039-44. PubMed ID: 15237430
[TBL] [Abstract][Full Text] [Related]
12. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
[TBL] [Abstract][Full Text] [Related]
14. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
15. Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.
Choi Y; Jeon YH; Jang JY; Chung JK; Kim CW
Mol Ther; 2011 May; 19(5):979-89. PubMed ID: 21063392
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model.
McConnell EJ; Pathangey LB; Madsen CS; Gendler SJ; Mukherjee P
J Surg Res; 2002 Oct; 107(2):196-202. PubMed ID: 12429175
[TBL] [Abstract][Full Text] [Related]
17. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
[TBL] [Abstract][Full Text] [Related]
18. Organ-specific pancreatic tumor growth properties and tumor immunity.
Morikane K; Tempero RM; Sivinski CL; Nomoto M; Van Lith ML; Muto T; Hollingsworth MA
Cancer Immunol Immunother; 1999 Jan; 47(5):287-96. PubMed ID: 10022473
[TBL] [Abstract][Full Text] [Related]
19. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
20. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
